Koji Shinoda

Koji Shinoda

Auto-generated profile, based on publicly available information

Koji Shinoda

Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
RLRui Li
Rui Li
TTThomas Tropea
Thomas Tropea
LBLaura Rosa Baratta
Laura Rosa Baratta
LZLeah Zuroff
Leah Zuroff
MDMaria E. Diaz-Ortiz
Maria E. Diaz-Ortiz
ABAmit Bar-Or
Amit Bar-Or
Background and Objectives There has been growing interest in potential roles of the immune system in the pathogenesis of Parkinson disease (PD). The aim of the current study was to comprehensively characterize phenotypic and functional profiles of circulating immune cells in patients with PD vs controls. Methods Peripheral blood was collected from patients with PD and age- and sex-matched neurologically normal controls (NCs) in 2 independent cohorts (discovery and validation). Comprehensive multicolor flow cytometry was performed on whole blood leukocytes and peripheral blood mononuclear cells to characterize different immune subsets and their ex vivo responses. Results The discovery cohort included 17 NCs and 12 participants with PD, and the validation cohort included 18 NCs and 18 participants with PD. Among major immune cell types, B cells appeared to be preferentially affected in PD. Proliferating B cell counts were decreased in patients with PD compared with controls. Proportions of B-cell subsets with regulatory capacity such as transitional B cells were preferentially reduced in the patients with PD, whereas proportions of proinflammatory cytokine-producing B cells increased, resulting in a proinflammatory shift of their B-cell functional cytokine responses. Unsupervised principal component analysis revealed increased expression of TNFα and GM-CSF by both B cells and T cells of patients with PD. In addition, levels of follicular T cells, an important B-cell helper T-cell population, decreased in the patients with PD, correlating with their B-cell abnormality. Discussion Our findings define a novel signature of peripheral immune cells and implicate aberrant Tfh:B-cell interactions in patients with PD.

12 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KSKoji Shinoda
Koji Shinoda
RLRui Li
Rui Li
ARAyman Rezk
Ayman Rezk
IMIna Mexhitaj
Ina Mexhitaj
KPKristina R. Patterson
Kristina R. Patterson
ABAmit Bar-Or
Amit Bar-Or
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting deeper depletion of CD20-expressing cells with repeat infusions. We assessed cellular immune profiles and their association with transient disease activity following anti-CD20 initiation as a window into relapsing disease biology. Peripheral blood mononuclear cells from independent discovery and validation cohorts of MS patients initiating ocrelizumab were assessed for phenotypic and functional profiles using multiparametric flow cytometry. Pretreatment CD20-expressing T cells, especially CD20 dim CD8 + T cells with a highly inflammatory and central nervous system (CNS)-homing phenotype, were significantly inversely correlated with pretreatment MRI gadolinium-lesion counts, and also predictive of early disease activity observed after anti-CD20 initiation. Direct removal of pretreatment proinflammatory CD20 dim CD8 + T cells had a greater contribution to treatment-associated changes in the CD8 + T cell pool than was the case for CD4 + T cells. Early disease activity following anti-CD20 initiation was not associated with reconstituting CD20 dim CD8 + T cells, which were less proinflammatory compared with pretreatment. Similarly, this disease activity did not correlate with early reconstituting B cells, which were predominantly transitional CD19 + CD24 high CD38 high with a more anti-inflammatory profile. We provide insights into the mode-of-action of anti-CD20 and highlight a potential role for CD20 dim CD8 + T cells in MS relapse biology; their strong inverse correlation with both pretreatment and early posttreatment disease activity suggests that CD20-expressing CD8 + T cells leaving the circulation (possibly to the CNS) play a particularly early role in the immune cascades involved in relapse development.

15 July 2019 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
YNYuri Nakamura
Yuri Nakamura
ZLZ. Liu
Z. Liu
SFS. Fukumoto
S. Fukumoto
KSK. Shinoda
K. Shinoda
ASA. Sakoda
A. Sakoda
JKJun-ichi Kira
Jun-ichi Kira
Background and purpose The cervical and thoracic cross‐sectional spinal cord area (CS‐SCA) in multiple sclerosis (MS) correlates with disability, whilst such a correlation remains to be established in neuromyelitis optica spectrum disorder (NMOSD). Our aim was to clarify differences between MS and NMOSD in spinal cord segments where CS‐SCA is associated with disability. Methods The CS‐SCA at C2/C3, C3/C4, T8/T9 and T9/T10 vertebral disc levels was measured in 140 MS patients (111 with relapsing–remitting MS and 29 with progressive MS) and 42 NMOSD patients with anti‐aquaporin‐4 immunoglobulin G. Disability was evaluated by Expanded Disability Status Scale (EDSS) scores. Multivariate associations between CS‐SCA and disability were assessed by stepwise forward multiple linear regression. Results Thoracic CS‐SCA was significantly smaller in NMOSD patients than in MS patients even after adjusting for age, sex and disease duration (P  =  0.002 at T8/T9), whilst there was no difference in cervical CS‐SCA between the two diseases. Cervical and thoracic CS‐SCA had a negative correlation with EDSS scores in MS patients (P  <  0.0001 at C3/C4 and P  =  0.0002 at T8/T9) whereas only thoracic CS‐SCA correlated with EDSS scores in NMOSD patients (P  =  0.0006 at T8/T9). By multiple regression analyses, predictive factors for disability in MS were smaller cervical CS‐SCA, progressive course, older age and a higher number of relapses, whilst those in NMOSD were smaller thoracic CS‐SCA and older age. Conclusions Thoracic CS‐SCA is a useful predictive marker for disability in patients with NMOSD whilst cervical CS‐SCA is associated with disability in patients with MS.

7 June 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PDF file
YHYu Hashimoto
Yu Hashimoto
KSKoji Shinoda
Koji Shinoda
ETEizo Tanaka
Eizo Tanaka
TUTaira Uehara
Taira Uehara
TMTakuya Matsushita
Takuya Matsushita
JKJun-ichi Kira
Jun-ichi Kira

1 June 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
SFShoko Fukumoto
Shoko Fukumoto
YNYuri Nakamura
Yuri Nakamura
MWMitsuru Watanabe
Mitsuru Watanabe
NINoriko Isobe
Noriko Isobe
TMTakuya Matsushita
Takuya Matsushita
JKJun-ichi Kira
Jun-ichi Kira
The effects of distinct HLA alleles on the brain and lesion volumes remain to be established, particularly in non-Caucasian populations. Two distinct susceptibility alleles, DRB1*15:01 and DRB1*04:05, are prevalent in the Japanese population; we therefore aimed to clarify the effects of HLA-DRB1 alleles on brain and lesion volumes in multiple sclerosis (MS). A total of 66 patients with MS (50 relapsing remitting, 16 progressive) underwent brain MRI volumetry measuring fluid-attenuated inversion recovery (FLAIR) and T1 lesion volumes, and normalized whole-brain (NWBV), white matter (NWMV), gray matter (NGMV), cortical gray matter (NCGMV), deep gray matter (NDGMV) and thalamus (NTV) volumes, and HLA-DRB1 genotyping. Carriers of HLA-DRB1*15:01(+)*04:05(-) and HLA-DRB1*15:01(-)*04:05(+) comprised 25.8% and 31.8% of patients, respectively. HLA-DRB1*15:01 carriers showed negative correlations between disease duration and NWBV (rs = -0.484, p = .036), NWMV (rs = -0.593, p = .008), and NTV (rs = -0.572, p = .011), and positive correlations between disease duration and FLAIR (rs = 0.539, p = .017) and T1 lesion volumes (rs = 0.545, p = .016). By contrast, no significant correlation of any MRI parameters with disease duration was found in HLA-DRB1*04:05 carriers. HLA-DRB1*15:01 carriers had a significantly faster reduction in NWBV and NWMV by disease duration and smaller NDGMV than DRB1*15:01 non-carriers, whereas HLA-DRB1*04:05 carriers had a significantly slower increase in FLAIR and T1 lesion volumes than HLA-DRB1*04:05 non-carriers. Our study suggests that distinct HLA-DRB1 alleles could differentially influence brain and lesion volumes over the disease course of MS.

26 February 2026 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
KSKoji Shinoda
Koji Shinoda
AMAyano Matsuyoshi
Ayano Matsuyoshi
HTHajime Takeuchi
Hajime Takeuchi
MWMitsuru Watanabe
Mitsuru Watanabe
KMKatsuhisa Masaki
Katsuhisa Masaki
NINoriko Isobe
Noriko Isobe
Background: The 2024 revised McDonald criteria for multiple sclerosis (MS) incorporate central vein sign (CVS) and paramagnetic rim lesion (PRL), but their utility in Asian patients remains unclear. Objective: To evaluate the performance of CVS, PRL and cortical lesion (CL) in distinguishing MS from neuromyelitis optica spectrum disorders (NMOSD) and myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in Japanese patients. Methods: We conducted a cross-sectional study of 139 MS, 41 NMOSD and 12 MOGAD patients who underwent 3-Tesla magnetic resonance imaging (MRI), including susceptibility-weighted imaging. Results: At least one CVS was identified in 95% of MS, 59% of NMOSD and 42% of MOGAD, while PRL occurred in 63% of MS only. The CVS number (cutoff ⩾ 2) yielded 85.6% sensitivity and 75.5% specificity (area under the curve (AUC) 0.856), which improved in patients <50 (AUC 0.920) or <70 years (AUC 0.907), and when combined with PRL and CL (AUC 0.926). The Select 6 algorithm achieved 69.1% sensitivity and 98.1% specificity (AUC 0.836), which were comparable in patients <50 (AUC 0.879) or <70 years (AUC 0.839), but improved when combined with PRL and CL (AUC 0.925). Conclusions: Combining Select 6 or CVS number with PRL and CL, particularly in patients <50 or <70 years, provides robust diagnostic performance for MS in the Asian population.